ConductScience.org, home

Paper41324846

Therapeutic effects and molecular mechanisms of isorhamnetin against pulmonary diseases.

Jing S and 3 others. Inflammopharmacology, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Therapeutic effects and molecular mechanisms of isorhamnetin against pulmonary diseases. Papers, record 41324846. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41324846

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Therapeutic effects and molecular mechanisms of isorhamnetin against pulmonary diseases.
PubMed
Journal
Inflammopharmacology
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-11-05
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jing SSiyuan
2Meng HHe
3Dong CChunling
4Li BBo

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
QuercetinMajor topic
Lung DiseasesMajor topic
Humans
Animals
COVID-19 Drug Treatment
COVID-19
Antiviral Agents
Anti-Inflammatory Agents

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
20220303001SFDepartment of Science and Technology of Jilin ProvincePubMed

Source PubMed

Download CSV of grants

References97

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134940580Metabolite and Bioactive Compounds Profiling of Meteora Sea Buckthorn Berries through High-Resolution NMR Analysis.Metabolites2021https://conductscience.org/library/papers/34940580PubMed
233252985Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.Am J Respir Crit Care Med2021https://conductscience.org/library/papers/33252985PubMed
335306954Isorhamnetin alleviates lipopolysaccharide-induced acute lung injury by inhibiting mTOR signaling pathway.Immunopharmacol Immunotoxicol2022https://conductscience.org/library/papers/35306954PubMed
435025963Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells.PLoS Pathog2022https://conductscience.org/library/papers/35025963PubMed
535086840Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis.Eur Respir J2022https://conductscience.org/library/papers/35086840PubMed
639073415Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: key drug screening and mechanism analysis.Naunyn Schmiedebergs Arch Pharmacol2025https://conductscience.org/library/papers/39073415PubMed
732774415Network Pharmacology Analysis and Experiments Validation of the Inhibitory Effect of JianPi Fu Recipe on Colorectal Cancer LoVo Cells Metastasis and Growth.Evid Based Complement Alternat Med2020https://conductscience.org/library/papers/32774415PubMed
833719855Potentiality of Moringa oleifera against SARS-CoV-2: identified by a rational computer aided drug design method.J Biomol Struct Dyn2022https://conductscience.org/library/papers/33719855PubMed
933842761
Analysis of Conformational, Structural, Magnetic, and Electronic Properties Related to Antioxidant Activity: Revisiting Flavan, Anthocyanidin, Flavanone, Flavonol, Isoflavone, Flavone, and Flavan-3-ol.
ACS Omega2021https://conductscience.org/library/papers/33842761PubMed
1037076602Therapeutic strategies for COVID-19: progress and lessons learned.Nat Rev Drug Discov2023https://conductscience.org/library/papers/37076602PubMed
1137673198Zhisou powder displays therapeutic effect on chronic bronchitis through inhibiting PI3K/Akt/HIF-1α/VEGFA signaling pathway and reprograming metabolic pathway of arachidonic acid.J Ethnopharmacol2024https://conductscience.org/library/papers/37673198PubMed
1237752734Natural compounds as possible anti-SARS-CoV-2 therapeutic agents: an in-vitro and in-silico study.Nat Prod Res2024https://conductscience.org/library/papers/37752734PubMed
1333149560Targeting the GRP78-Dependant SARS-CoV-2 Cell Entry by Peptides and Small Molecules.Bioinform Biol Insights2020https://conductscience.org/library/papers/33149560PubMed
1435942366Study on the Action Mechanism of the Yifei Jianpi Tongfu Formula in Treatment of Colorectal Cancer Lung Metastasis Based on Network Analysis, Molecular Docking, and Experimental Validation.Evid Based Complement Alternat Med2022https://conductscience.org/library/papers/35942366PubMed
1531112383Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome.N Engl J Med2019https://conductscience.org/library/papers/31112383PubMed
1631467176Isorhamnetin inhibited migration and invasion via suppression of Akt/ERK-mediated epithelial-to-mesenchymal transition (EMT) in A549 human non-small-cell lung cancer cells.Biosci Rep2019https://conductscience.org/library/papers/31467176PubMed
1735528163Network Pharmacological Analysis and Experimental Study of the Antipharyngitis Mechanism of the Chaiqin Qingning Capsule.Biomed Res Int2022https://conductscience.org/library/papers/35528163PubMed
1832914113Fat-lowering effects of isorhamnetin are via NHR-49-dependent pathway in Caenorhabditis elegans.Curr Res Food Sci2020https://conductscience.org/library/papers/32914113PubMed
1937839759Isorhamnetin as a novel inhibitor of pneumolysin against Streptococcus pneumoniae infection in vivo/in vitro.Microb Pathog2023https://conductscience.org/library/papers/37839759PubMed
2033519145Evaluating the potency of Sulawesi propolis compounds as ACE-2 inhibitors through molecular docking for COVID-19 drug discovery preliminary study.J King Saud Univ Sci2021https://conductscience.org/library/papers/33519145PubMed

See all 97 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41324846

GET https://conductscience.org/api/papers/v1/41324846/references?page=2